



Mahidol University
Faculty of Medicine Ramathibodi Hospital

HPB surgery complications


F Ativitch Asavachaisuvikom

Asst. Prof. Pongsatorn Tangtawee

HPB surgery unit, Faculty of Medicine, Ramathibodi hospital, Mahidol University

In this year...



 **Mahidol University**
Faculty of Medicine Ramathibodi Hospital

**Post hepatectomy
liver failure**

F Ativitch Asavachaisuvikom
HPB unit, Department of Surgery, Ramathibodi hospital

CBD injury

F Sukhum Kobdej
Advisor Dr Pongsatorn Tangtawee

Posthepatectomy Bile Leakage

F Sukhum Kobdej

Outline

- Postoperative pancreatotomy fistula(POPF)
- Postpancreatectomy hemorrhage(PPH)
- Delayed gastric emptying (DGE)
- Post-pancreatectomy acute pancreatitis(PPAP)
- Posthepatectomy hemorrhage



“Eat When You Can, Sleep When You Can, and
Don’t Mess with the Pancreas”

Nipun B. Merchant, MD, FACS

Division of Surgical Oncology


Introduction

- Early series published in the late 1960s reported postoperative morbidity rates of 60% and mortality rates approaching 25%.
- Recent series from specialized surgical centers have reported mortality rates following PD to be less than 5%


Postoperative pancreatic fistula(POPF)

- Definition,
“Pancreatic fistula remains an abnormal communication between the pancreatic ductal “system” and another epithelial surface containing pancreas-derived, enzyme-rich fluid”
- For the diagnosis,
“any measurable volume of drain fluid on/after POD 3
with amylase level >3 times UNL”

2005



2016





>x3 Institutional normal
serum amylase value


Clinically relevant change
in management of POPF

Amylase >3 times upper limit
institutional normal serum amylase
value

**Biochemical Leak
(BL)**







Event	2005 ISGPF	2016 ISGPS
Percutaneous or endoscopic drainage	Grade C/Grade B (unclear)	Grade B
Angiographic procedures for POPF related bleeding	Grade C	Grade B
Organ Failure	Not included	Grade C
Sepsis	Grade C	Not included
All events and treatment on POPF classification must be POPF-related	No	Yes

Increase incidence of POPF grade B but **more severe** in grade C
(ICU stay, LOS, readmission rate, hospital costs, morbidity, 90-days mortality ($P < 0.001$))

Postoperative pancreatic fistula(POPF)

- The most common complication occurring 10 - 34% in high volume center
- In Ramathibodi hospital, incidence 19.1% (grade B + C) after PD
- The updated classification, distal pancreatectomy is characterized by a lower than pancreaticoduodenectomy POPF rate, but by a higher BL incidence
- Possible to develop of complicated septic and/or hemorrhagic form

Can we predict POPF ?

	Fistula risk score (Callery 2013) ¹	Modified Fistula Risk Score (m-FRS) (Kantor 2017) ²	Alternative Fistula Risk Score (a-FRS) (Mungroop 2019) ³	French POPF score (Tabchouri 2021) ⁴
Preoperative	AdenoCA/chronic pancreatitis = 0 Others = 2	Sex: female 0; male 2 BMI (kg/m2): < 25 = 0; ≥25=1 Bilirubin (mg/dL): ≥2=0;<2=1	BMI (kg/m2): linear variable	Age: linear variable Preoperative radiotherapy or radiochemotherapy
Intraoperative	Pancreatic texture (hard = 0, soft/friable = 2) MPD size (≥5mm = 0, 4mm =1, 3mm=2,2mm=3, ≤1mm=4) Blood loss (≤400ml=0, 401-700ml=1, 701-1000ml=2, >1000ml=3)	Pancreas texture: Hard/intermediate =0; soft=2 Wirsung size (mm): ≥6=0; 3-6=3; <3=4	Pancreas texture: soft: no 0; yes 1 Wirsung size (mm) linear variable	Pancreas texture: soft: no 0; yes 1 Wirsung size (mm) linear variable
POPF risk	0 = 0% 1-2 = Low(6%) 3-6 = Moderate(22%) 7-10 = High(88%)	0-2 = 0% 3-6 = Low(<10%) 7-8 = Moderate(10-20%) 9-10 = High(>20%)	Low 0—5% Moderate (> 5—20%) High (> 20%)	Negligible (1%) if < 0.25 Low (2%) if 0.25—0.5 Moderate (8%) if 0.5—0.75 High (30%) if > 0.75

¹Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg 2013;216:1—14.

²Kantor O, Talamonti MS, Pitt HA, et al. Using the NSQIP Pancreatic Demonstration Project to Derive a Modified Fistula Risk Score for Preoperative Risk Stratification in Patients Undergoing Pancreaticoduodenectomy. J Am Coll Surg. 2017 May;224(5):816 -825.

³Mungroop TH, van Rijssen LB, van Klaveren D, et al. Alternative Fistula Risk Score for pancreatoduodenectomy (a- FRS): design and international external validation. Ann Surg 2019;269:937—43.

⁴Tabchouri N, Bouquot M, Hermand H, et al. A novel pan- creatic fistula risk score including preoperative radiation therapy in pancreatic cancer patients. J Gastrointest Surg 2021;25:991—1000.

A Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic Fistula

A classification of the International Study Group of Pancreatic Surgery

Fabian Schuh, MD, André L. Mihaljevic, MD, MSc,*† Pascal Probst, MD,*
Maxwell T. Trudeau, MD,‡ Philip C. Müller, MD,§ Giovanni Marchegiani, MD,||
Marc G. Besselink, MD, PhD,¶ Faik Uzunoglu, MD,# Jakob R. Izbicki, MD,#
Massimo Falconi, MD,** Carlos Fernandez-del Castillo, MD, PhD,††
Mustapha Adham, MD,‡‡ Kaspar Z'graggen, MD,§ Helmut Friess, MD,§§
Jens Werner, MD,||| Jürgen Weitz, MD,¶¶ Oliver Strobel, MD,* Thilo Hackert, MD,*
Dejan Radenkovic, MD,## Dezso~Kelemen, MD,*** Christopher Wolfgang, MD,†††
Y. I. Miao, MD,‡‡‡ Shailesh V. Shrikhande, MD, PhD,§§§ Keith D. Lillemoe, MD,|||
Christos Dervenis, MD,¶¶¶ Claudio Bassi, MD,|| John P. Neoptolemos, MD,*
Markus K. Diener, MD,*† Charles M. Vollmer, Jr., MD,‡
and Markus W. Büchler, MD*✉*

Type A: not-soft pancreatic texture AND main pancreatic duct size > 3mm

Type B: not-soft pancreatic texture AND main pancreatic duct size ≤ 3mm

Type C: soft pancreatic texture AND main pancreatic duct size > 3mm

Type D: soft pancreatic texture AND main pancreatic duct size ≤ 3mm

A Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic Fistula

A classification of the International Study Group of Pancreatic Surgery

Fabian Schuh, MD, André L. Mihaljevic, MD, MSc,*† Pascal Probst, MD,*
Maxwell T. Trudeau, MD,‡ Philip C. Müller, MD,§ Giovanni Marchegiani, MD,||
Marc G. Besselink, MD, PhD,¶ Faik Uzunoglu, MD,# Jakob R. Izbicki, MD,#
Massimo Falconi, MD,** Carlos Fernandez-del Castillo, MD, PhD,††
Mustapha Adham, MD,‡‡ Kaspar Z'graggen, MD,§ Helmut Friess, MD,§§
Jens Werner, MD,||| Jürgen Weitz, MD,¶¶ Oliver Strobel, MD,* Thilo Hackert, MD,*
Dejan Radenkovic, MD,## Dezso~Kelemen, MD,*** Christopher Wolfgang, MD,†††
Y. I. Miao, MD,‡‡‡ Shailesh V. Shrikhande, MD, PhD,§§§ Keith D. Lillemoe, MD,|||||
Christos Dervenis, MD,¶¶¶ Claudio Bassi, MD,|| John P. Neoptolemos, MD,*
Markus K. Diener, MD,*† Charles M. Vollmer, Jr., MD,‡
and Markus W. Büchler, MD*✉*

A systematic review, 108 studies, 14471 patients

Soft pancreatic texture was significantly associated with the development of CR-POPF

(OR 4.24, 95% CI 3.67-4.89, $P < 0.01$)

MPD diameter ≤ 3 mm significantly increased CR-POPF risk (OR 3.66, 95% CI 2.62–5.12, $P < 0.01$)

A Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic Fistula

A classification of the International Study Group of Pancreatic Surgery

Fabian Schuh, MD, André L. Mihaljevic, MD, MSc,*† Pascal Probst, MD,* Maxwell T. Trudeau, MD,‡ Philip C. Müller, MD,§ Giovanni Marchegiani, MD,|| Marc G. Besselink, MD, PhD,¶ Faik Uzunoglu, MD,# Jakob R. Izbicki, MD,# Massimo Falconi, MD,** Carlos Fernandez-del Castillo, MD, PhD,†† Mustapha Adham, MD,‡‡ Kaspar Z'graggen, MD,§ Helmut Friess, MD,§§ Jens Werner, MD,||| Jürgen Weitz, MD,¶¶ Oliver Strobel, MD,* Thilo Hackert, MD,* Dejan Radenkovic, MD,## Dezso~Kelemen, MD,*** Christopher Wolfgang, MD,††† Y. I. Miao, MD,‡‡‡ Shailesh V. Shrikhande, MD, PhD,§§§ Keith D. Lillemoe, MD,||| Christos Dervenis, MD,¶¶¶ Claudio Bassi, MD,|| John P. Neoptolemos, MD,* Markus K. Diener, MD,*† Charles M. Vollmer, Jr., MD,‡ and Markus W. Büchler, MD*✉*


		No. of Patients	No. of Patients		
		Without CR-POPF	With CR-POPF	Rates	P
A	Not-soft pancreatic texture and MPD > 3 mm	1533	56	3.5%	0.002
B	Not-soft pancreatic texture and MPD ≤ 3 mm	854	56	6.2%	<0.001
C	Soft pancreatic texture and MPD > 3 mm	847	169	16.6%	<0.001
D	Soft pancreatic texture and MPD ≤ 3 mm	1547	471	23.2%	
		4781	752	15.7%	Overall P < 0.001

Distal Pancreatectomy Fistula Risk Score (D-FRS)

Development and International Validation

De Pastena, Matteo MD, PhD^{*,†}; van Bodegraven, Eduard A. MD[†]; Mungroop, Timothy H. MD[†]; Vissers, Frederique L. MD[†]; Jones, Leia R. BSc^{†,‡}; Marchegiani, Giovanni MD, PhD^{*}; Balduzzi, Alberto MD^{*}; Klompmaker, Sjors MD, MSc, PhD^{†,§}; Paiella, Salvatore MD, PhD^{*}; Tavakoli Rad, Shazad[†]; Groot Koerkamp, Bas MD, PhD[†]; van Eijck, Casper MD, PhD[†]; Busch, Olivier R. MD, PhD[†]; de Hingh, Ignace MD, PhD[¶]; Luyer, Misha MD, PhD[¶]; Barnhill, Caleb MD[#]; Seykora, Thomas MD^{**}; Maxwell T, Trudeau ^{**}; de Rooij, Thijs MSc[†]; Tuveri, Massimiliano MD^{*}; Malleo, Giuseppe MD, PhD^{*}; Esposito, Alessandro MD^{*}; Landoni, Luca MD^{*}; Casetti, Luca MD, PhD^{*}; Alseidi, Adnan MD, PhD^{#,††}; Salvia, Roberto MD, PhD^{*}; Steyerberg, Ewout W.^{‡‡}; Abu Hilal, Mohammad MD, MSc, PhD^{‡,§§}; Vollmer, Charles M. MD^{**}; Besselink, Marc G. MD, MSc, PhD[†]; Bassi, Claudio MD, FRCS, FACS, FEBS, FASA (Hon.)^{*}

Dutch pancreatic cancer group
<https://www.evidencio.com/models/show/2587>



Postoperative pancreatic fistula(POPF)



Journal of Gastrointestinal Surgery

Volume 28, Issue 9, September 2024, Pages 1406-1411





5694 patients with POPF grade(B/C)

How to prevent it ?

Increase 30-day readmission and mortality

Original
Impact
on
cost
of
Improvement Program data

Abdullah Khalid^a  , Neda Amini^a, Shamsher A. Pasha^b, Lyudmyla Demyan^a,
Elliot Newman^c, Daniel A. King^d, Danielle DePeralta^d, Sepideh Gholami^d, Gary B. Deutsch^d,
Marcovalerio Melis^c, Matthew J. Weiss^d

Prevention

- Technical
 - Pancreaticojejunostomy vs Pancreaticogastrostomy
 - Modified Blumgart PJ vs Pancreaticogastrostomy
 - PJ with external stent vs PG with external stent
 - P-duct stent
 - Omental roll up
- Medication
 - Somatostatin analogue



Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy (Review)

Cheng Y, Briarava M, Lai M, Wang X, Tu B, Cheng N, Gong J, Yuan Y, Pilati P, Mocellin S

- 10 RCTs that enrolled a total of 1629 participants.
- Effects of pancreaticogastrostomy compared to pancreaticojejunostomy on postoperative pancreatic fistula

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)
	Risk with PG	Risk with PJ			
Postoperative pancreatic fistula (Grade A, B or C) Follow up: 30 days	214 per 1000	254 per 1000	RR 1.19 (0.88 to 1.62)	1513 (9 studies)	⊕⊕⊕⊕ Low a,b,c

No statistical difference

ORIGINAL ARTICLE



Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy

Shin-E. Wang, Shih-Chin Chen, Bor-Uei Shyr & Yi-Ming Shyr

Department of Surgery, Taipei Veterans General Hospital, National Yang Ming University, Taipei, Taiwan, ROC

- 206 patients undergoing PD, Prospectively data collection
- Blumgart PJ was associated with shorter postoperative hospital stay (median (range) 25 (10–99) vs. 27 (10–97) days, $P = 0.022$).
- Surgical mortality in Blumgart PJ vs PG(0 vs 4.9%, $P = 0.030$).
- The CR-POPF by Blumgart PJ is significantly lower than that by PG for overall patients (7% vs. 20%, $P = 0.007$), especially for those in intermediate fistula risk zone (6% vs. 21%, $P = 0.048$) and high fistula risk zone (14% vs. 47%, $P = 0.038$)

HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)



Slide 21/78

JAMA Surgery | Original Investigation

Pancreaticojejunostomy With Externalized Stent vs Pancreaticogastrostomy With Externalized Stent for Patients With High-Risk Pancreatic Anastomosis

A Single-Center, Phase 3, Randomized Clinical Trial

Stefano Andrianello, MD; Giovanni Marchegiani, MD, PhD; Giuseppe Malleo, MD, PhD; Gaia Masini, MD; Alberto Balduzzi, MD; Salvatore Paiella, MD, PhD; Alessandro Esposito, MD; Luca Landoni, MD; Luca Casetti, MD, PhD; Massimiliano Tuveri, MD; Roberto Salvia, MD, PhD; Claudio Bassi, MD

Table 2. Primary Outcome of Postoperative Pancreatic Fistula


Characteristic	PJ (n = 36)	PG (n = 36)	Risk Ratio (95% CI)	P Value
POPF, No. (%)	14 (38.9)	18 (50.0)	0.778 (0.461-1.313)	.48
BL, No. (%)	5 (13.9)	2 (5.6)	2.535 (0.518-12.058)	.43
Grade B, No. (%)	14 (38.9)	14 (38.9)	NA	.11
Grade C, No. (%)	0	4 (11.1)		

Table 3. Postoperative Complications

Characteristic	No. (%)			
	PJ (n = 36)	PG (n = 36)	Risk Ratio (95% CI)	P Value
Clavien-Dindo score ≥III	8 (22.2)	17 (47.2)	0.471 (0.233-0.949)	.047


HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

A Pancreaticojejunostomy



Cattel-Warren duct-to-mucosa technique

B Pancreaticogastrostomy





Review

Does pancreatic duct stent placement lead to decreased postoperative pancreatic fistula rates after pancreaticoduodenectomy? A meta-analysis

Chenchen Guo^{a,*}, Bin Xie^b, Diandian Guo^c

^a Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, 230001, China

^b Anhui Normal University, Wuhu, Anhui, 241000, China

^c School of Medicine, Southeast University, Nanjing, 210009, China

Source	Anastomosis technique	Internal/ external stents	Type of stent	POPF assessment scale	Prophylactic octreotide
Cai 2022	Bing's anastomosis	Internal stent	–	ISGPF definition	–
Singh 2021	end-to-side, duct-to-mucosa, PJ anastomosis	internal stent	a 5 cm #5 French polyvinyl chloride infant feeding tube	ISGPF definition	Octreotide (100 mcg)
Qureshi 2018	end-to-side, mucosa-to-mucosa, PJ anastomosis	external stent	–	ISGPF definition	–
Motoi 2012	end-to-side, duct-to-mucosa, PJ anastomosis	external stent	a 5-Fr polyvinyl catheter	ISGPF definition	Not
Pessaux 2011	end-to-side, duct-to-mucosa, PG anastomosis or end-to-side, duct-to-mucosa, PJ anastomosis	external stent	a Fr 3 to 6 polyvinyl catheter with multiple side-holes	ISGPF definition	Octreotide (100µg, 3 times a day)
Poon 2007	end-to-side, duct-to-mucosa, PJ anastomosis	external stent	a Fr 3–8 polyvinyl catheter with multiple side-holes	>10 ml/day (3 times serum level) more than 3 days after surgery	Not
Winter 2006	end-to-side, duct-to-mucosa, PJ anastomosis or end-to-end, invagination, PJ anastomosis	Internal stent	A 3.5 to 8 French plastic pediatric feeding tube, length of 6 cm	ISGPF definition and JHH definition	Not

Subgroup analysis of the effect of pancreatic duct stents on POPF.

Subgroup analyses	Studies, n	Patients, n	Pooled RR (95% CI)	I ² (%)	p-value	p-value
All studies	7	847	0.85 (0.57–1.26)	51	0.41	–
Ways of drainage						
internal	3	374	1.25 (0.87–1.80)	0	0.22	0.005
external	4	473	0.61 (0.43–0.86)	79	0.005	
prophylactic octreotide						
Yes	2	208				
Not	3	447				
surgical approaches						
open	6	757				
laparoscopic	1	90				

POPF, postoperative pancreatic fistula; RR, relative risk; CI, confidence interval; N







Fig. 3. Forest plot of the comparisons of outcomes between the stent group and the non-stent group: pancreatic fistula.

Prospective randomized controlled trial of omental roll-up technique on pancreatojejunostomy anastomosis for reducing perioperative complication in patients undergoing pancreatoduodenectomy

Pongsatorn Tangtawee | Somkit Mingphruedhi | Narongsak Rungsakulkij  |
Wikran Suragul | Watoo Vassanasiri | Paramin Muangkaew 

- Prospectively RCT, N = 24 patients
- The incidence of POPF was not different between the omental roll-up group (n = 5, 14.7%) and non-omental roll-up group (n = 7, 20.6%) (P = 0.525).
- No differences were found in postoperative hemorrhage after pancreatotomy, delayed gastric emptying, and chyle leakage between the groups.



Prophylactic octreotide for postoperative pancreatic fistula in patients with pancreatoduodenectomy

Risk-stratified analysis

So Jeong Yoon, MD, Okjoo Lee, MD, Ji Hye Jung, MD, Sang Hyun Shin, MD, PhD, Jin Seok Heo, MD, PhD, In Woong Han, MD, PhD



Contents lists available at ScienceDirect

Hepatobiliary & Pancreatic Diseases International

journal homepage: www.elsevier.com/locate/hbpd



Original Article/Pancreas

Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: A prospective randomized trial

Ayman El Nakeeb*, Ahmed ElGawalby, Mahmoud A. Ali, Ahmed Shehta, Hosam Hamed, Mohamed El Refea, Ahmed Moneer, Ahmed Abd El Rafee

Gastroenterology Surgical Center, Mansoura University, Mansoura 35516, Egypt

RANDOMIZED CONTROLLED TRIAL

Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial

A FRENCH 007—

Sébastien Gaujoux, MD, PhD,*✉ Jean-
Guillaume Piessen, MD, PhD,||| Stép
Frantz Foissac, PhD,** Louise
Emmanuel Buc, MD, PhD,\$\$||| Muste
David Fuks, MD, PhD,**+†† Sophie
Fabrice Muscarei, MD, PhD,|||††† Laure
Jean-Christophe Vaillant, MD, PhD,*† Lilian Schwarz, MD, PhD,+++++
Antonio Sa Cunha, MD, PhD,\$\$\$||| Milena Muzzalini, MD,*
HPB surgery complications: Ativitch Asavachaisuvikorn MD

HPB surgery complications: Ativitch Asavachaisuvikom MD.(F)

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-asianjournalsurgery.com



ORIGINAL ARTICLE

Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy

Dong Do You ^a, Kwang Yeol Paik ^{b,*}, Il Young Park ^c,
Young Kyung Yoo ^d



World J Surg

<https://doi.org/10.1007/s00268-019-04956-6>




SCIENTIFIC REVIEW

The Use of Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials

A. Adiamah¹ · Z. Arif¹ · F. Berti¹ · S. Singh¹ · N. Laskar¹ · D. Gomez¹

Not effectively for decreasing incidence of POPF





Original Article

Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? — A systematic review with meta-analysis of randomized-controlled trials

Stephan Schorn^{a,*}, Thomas Vogel^a, Ihsan Ekin Demir^{a,b}, Elke Demir^a, Okan Safak^a, Helmut Friess^a, Güralp Onur Ceyhan^b

^a Technical University of Munich, School of Medicine, Klinikum Rechts der Isar, Department of Surgery, Germany

^b Department of General Surgery, HPB-Unit, School of Medicine, Acibadem Mehmet Ali Aydınlar University, Istanbul, Turkey





Characteristics of the included studies.

Study	Somatostatin-analogue	Definition of POPF	Blinding	Surgery
Allen et al., 2014	Perioperative pasireotide 900 µg 2× day for 7 days	ISGPF	Double blinded	PD + DP
Büchler et al., 1991	Perioperative octreotide 100 µg 3× day for 7 days	Amylase and lipase >3 times serum concentration, >3 days postop, >10 ml/h	Double blinded	PD + DP
El Nakeeb et al., 2017	Perioperative octreotide 100 µg 3× day until time of resumption of oral fluids intake	ISGPF	Na	PD
Fernández-Cruz et al., 2012	Perioperative octreotide 100 µg 3× day for 10 days	ISGPF	Na	PD
Friess et al., 1995	Perioperative octreotide 100 µg 3× day for 7 days	Amylase and lipase >3 times serum level, >3 days postop, >10 ml/h	Double blinded	PD + DP
Gouillat et al., 2001	Perioperative somatostatin 250 µg/h for 7 days	>100 ml/day exceeding 5 times normal serum amylase after POD 3, persisting after POD 12 or in association with clinically relevant symptoms requiring surgery, drainage or intensive care	Double blinded	PD
Hesse et al., 2005	Perioperative octreotide 100 µg 3× day for 7 days	>100 ml/day exceeding 5 times normal serum amylase after POD 3, persisting after POD 12 or in association with clinically relevant symptoms requiring surgery, drainage or intensive care	Open	PD + DP
Katsourakis et al., 2013	Perioperative somatostatin 250 µg/h for 6 days	ISGPF	Na	PD + DP
Klempa et al., 1991	Perioperative somatostatin 250 µg/h for 7 days	—	Na	PD
Kollmar et al., 2008	Perioperative octreotide 100 µg 3× day for 7 days	ISGPF	Double blinded	PD
Kurumboor et al., 2015	Perioperative octreotide 100 µg 3× day for 6 days	ISGPF	Open	PD
Lowy et al., 1997	Perioperative octreotide 150 µg 3× day for 6 days	drainage of amylase-rich fluid (>2.5 times the upper limit of normal for serum amylase) and clinical signs or the need of reintervention	Na	PD
Montorsi et al., 1995	Perioperative octreotide 100 µg 3× day for 7 days	>10 ml/day fluids exceeding 3 times normal serum amylase after POD 3	Double blinded	PD + DP
Pederzoli et al., 1994	Perioperative octreotide 100 µg 3× day for 7 days	>10 ml/day for >4 days after POD 4, amylase >3 times normal	Double blinded	PD + DP
Sarr et al., 2003	Perioperative vapreotide 600 µg 2× day for 7 days	>30 ml/day 5, amylase or lipase >5 times normal	Double blinded	PD + DP
Shan et al., 2005	Perioperative somatostatin 250 µg/h for 7 days	>10 ml/day fluids exceeding amylase >3 times serum level for >7 days	Na	PD
Suc et al., 2004	Perioperative octreotide 100 µg 3× day for 10 days	Fluids exceeding >4 times normal serum level or any radiological signs of POPF	Single blinded	PD + DP
Yeo et al., 2000	Perioperative octreotide 250 µg 3× day for 7 days	>50 ml/day fluids exceeding >3 times normal serum value on or after day 10 or radiological signs of POPF	Double blinded	PD



Original Article

Prophylactic somatostatin analogs for postoperative pancreatic fistulas: a cross-sectional survey of AHPBA surgeons

Sardar Shahmir B. Chauhan¹, Benjamin Vierra¹, James O. Park^{1,3}, Venu G. Pillarisetty^{1,3},
Giana H. Davidson^{1,2}, Jonathan G. Sham^{1,2,3}  

Results

One hundred and two surgeons responded in spring 2023. 48.0% of respondents reported using prophylactic SSAs during their surgical training, however, only 29.4% do so in their current practice, most commonly when performing Whipple procedures. Octreotide was the most frequently used SSA (34.3%), followed by octreotide LAR (12.7%) and pasireotide (11.8%). Reasons for not prescribing included a lack of high-quality data (62.7%), perception of limited efficacy (34.3%) and high cost (30.4%).

Currently trend

29.4% used in current practice

Reasons for not prescribing

- Lack of high quality data(62.7%)
- Limited efficacy(34.4%)
- High cost(30.4%)

Management

The aim of this management is to

- control the patient's fluid
- electrolyte
- nutritional status

Management

Monitoring

- Clinical (vital constants, abdominal pain, feeding, transit, appearance and quantity of drained fluids, skin condition at the drain orifice if POPF is prolonged or high-flow, biological result(haemoglobin, leukocytosis, CRP, creatinine))
- Fluid and electrolyte rebalancing
- Routine CT scan?

Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial

F Jasmijn Smits*, Anne Claire Henry*, Marc G Besselink, Olivier R Busch, Casper H van Eijck, Mark Arntz, Thomas L Bollen, Otto M van Delden, Daniel van den Heuvel, Christiaan van der Leij, Krijn P van Lienden, Adriaan Moelker, Bert A Bonsing, Inne H Borel Rinkes, Koop Bosscha, Ronald M van Dam, Wouter J M Derksen, Marcel den Dulk, Sebastiaan Festen, Bas Groot Koerkamp, Robbert J de Haas, Jeroen Hagendoorn, Erwin van der Harst, Ignace H de Hingh, Geert Kazemier, Marion van der Kolk, Mike Liem, Daan J Lips, Misha D Luyer, Vincent E de Meijer, J Sven Mieog, Vincent B Nieuwenhuijs, Gijs A Patijn, Wouter W te Riele, Daphne Roos, Jennifer M Schreinemakers, Martijn W J Stommel, Fennie Wit, Babs A Zonderhuis, Lois A Daamen, C Henri van Werkhoven, I Quintus Molenaar†, Hjalmar C van Santvoort†, for the Dutch Pancreatic Cancer Group

- Jan 2018 to Nov 2019, all 1805 patients who had pancreatic resection in multi high volume center in Netherland
- 1748 patients (885 receiving usual care and 863 receiving algorithm-center care)



Daily evaluation parameters on each postoperative day 3–14


Physical examination
Heart rate
Respiratory rate
Temperature

Drain output
Volume
Quality
Amylase


Blood test
White blood cells
C-reactive protein

Clinical judgement made by the treating surgeon


1 Indication for CT scan



2 Antibiotic treatment




3 Removal of drains



Slide 30/78

HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)



	Intervention (n=863)	Control (n=885)	Adjusted risk ratio (95% CI)*	p value
Clinical events†				
Postoperative pancreatic fistula	239/863 (28%)	187/885 (21%)	1.23 (0.97–1.56)	0.084
Postoperative bile leak‡	66/643 (10%)	57/671 (8%)	0.90 (0.60–1.33)	0.59
Gastroenterostomy leak‡	8/643 (1%)	11/671 (2%)	0.88 (0.30–2.62)	0.82
Chyle leak	61/863 (7%)	69/885 (8%)	0.95 (0.59–1.54)	0.84
Delayed gastric emptying			1.17 (0.76–1.80)	0.48

Not difference

HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

	Intervention (n=863)	Control (n=885)	Adjusted risk ratio (95% CI)	p value
Primary composite outcome of at least one of bleeding that required invasive intervention, organ failure, or 90-day mortality	73 (8%)	124 (14%)	0.48 (0.38–0.61)	<0.0001
Secondary outcomes for the individual components of the primary outcome				
Bleeding that required intervention	47 (5%)	51 (6%)	0.65 (0.42–0.99)	0.046
New-onset organ failure	39 (5%)	92 (10%)	0.35 (0.20–0.60)	0.0001
Circulatory failure	28 (3%)	70 (8%)	0.32 (0.23–0.46)	<0.0001
Respiratory failure	22 (3%)	55 (6%)	0.35 (0.24–0.50)	<0.0001
Renal failure	12 (1%)	29 (3%)	0.37 (0.16–0.85)	0.019
90-day mortality	23 (3%)	44 (5%)	0.42 (0.28–0.63)	0.029

Less incidence of bleeding that required invasive intervention and new onset organ failure

Management

Nutrition

- NPO vs Enteral feeding vs TPN

ISGPS 2016

BL : oral

grade B or C : may related with complication, suggest enteral nutrition or fasting with TPN

- Caloric goals : cover at least 80% of energy requirements (calculated by the 25 — 30 kcal/kg/day formula) to facilitate closure of the POPF and reduce the risk of complications
- Continued oral feeding is easier with PJ than with PG, because with the latter the flow of food can increase the flow rate of drainage from the POPF

HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

Slide 32/78


Management

Ann Surg Oncol (2015) 22:3905–3912
DOI 10.1245/s10434-015-4496-1

Annals of
SURGICAL ONCOLOGY
OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY



ORIGINAL ARTICLE – PANCREATIC TUMORS



HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

TABLE 2 Postoperative complications

	DI group (n = 30)	NDI group (n = 29)	p value
POPF			.3284
Grade A	10	10	
Grade B	20	17	
Grade C	0	2	
Clinically relevant POPF (grade B/C)	20	19	.9257
POPF-related hemorrhage	0	2	.1434
Length of drain placement (days) ^a	27 (7–80)	26 (7–70)	.8858
Delayed gastric emptying			.3574
Grade A	1	0	
Grade B	1	3	
Grade C	0	0	
Intra-abdominal abscess	1	2	.5334
Biliary leakage	0	0	1.0000
Ileus	1	0	.3214
Bacteremia	0	2	.1434
Wound infection	1	1	.9805
Peptic ulcer	1	0	.3214
Cholangitis	1	0	.3214
Others	4	2	.4135
Postoperative fasting period (days) ^a	5 (5–25)	23 (7–70)	<.0001
Drainage output volume (mL) ^a			
POD 1	170 (52–385)	213 (51–600)	.7587
POD 3	32.5 (2–1670)	44 (2–187)	.6347
POD 5	10 (2–845)	21 (2–221)	.2661
POD 7	10.5 (2–865)	15 (0–225)	.6891
Postoperative hospital stay (days) ^a	29.5 (16–88)	29 (17–78)	.4661
Reoperation	0	0	1.0000
Readmission	2	2	.9720
Mortality	0	0	1.0000

DI dietary intake, NDI no dietary intake, POPF postoperative pancreatic fistula, POD postoperative day




^a Values are median (range)

Slide 33/78

Management

Randomized clinical trial


Randomized trial of oral *versus* enteral feeding for patients with postoperative pancreatic fistula after pancreatoduodenectomy

J.-M. Wu¹ , T.-C. Kuo¹, H.-A. Chen⁶, C.-H. Wu¹, S.-R. Lai², C.-Y. Yang¹, S.-Y. Hsu³, T.-W. Ho⁴, W.-C. Liao^{5,7}  and Y.-W. Tien¹ 

Departments of ¹Surgery, ²Nutrition, ³Nursing, ⁴Bioinformatics and ⁵Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, ⁶Department of Surgery, Shuang Ho Hospital, Taipei Medical University College of Medicine, and ⁷Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

Correspondence to: Dr Y.-W. Tien, Department of Surgery, National Taiwan University Hospital, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei 100, Taiwan (e-mail: ywtien5106@ntu.edu.tw)

	Enteral feeding (n = 57)	Oral feeding (n = 57)	P for superiority‡	P for non-inferiority#
Efficacy outcome				
Fistula closure within 30 days	51 (89; 79, 96)	50 (88; 76, 95)	–	0.020 (ITT) 0.011 (PP)
Time to fistula closure (days)*	17 (16–20; 16, 20)	17 (15–20; 15, 20)	0.617§	
Grade of fistula			0.582	
A	32 (56)	28 (49)		
B				
C				
Duration				
Cost after				
Safety of				
Fever/				
Fluid o				
Pneum				
Postp				
Diarrho				
Readmission				



Oral feeding in patients with POPF after pancreatoduodenectomy did not increase the duration or grade of POPF, and was associated with reduced duration of stay and hospital costs

Management

Medication


- Somatostatin analogue

No clear recommendations

Intervention

- Pancreatic duct stent
 - Retrospective study ; ERCP with p-duct stent was not seen benefit in distal pancreatectomy

Management



ORIGINAL ARTICLE

Reoperation for pancreatic fistula: a systematic review of completion pancreatectomy vs. pancreas-preserving-procedures and outcomes

Alessio Marchetti^{1,2,*}, Gaetano Corvino^{1,*}, Giampaolo Perri³, Giovani Marchegiani³ & Raffaele De Luca⁴

¹Department of Pancreatic Surgery, Verona University Hospital, Piazzale Ludovico Antonio Scuro 10, 37134, Verona, VR, Italy, ²Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, 550 First Avenue, New York, NY, 10016, USA, ³Hepato Pancreato Biliary (HPB) and Liver Transplant Surgery, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Via Giustiniani 2, 35128, Padova, and ⁴Department of Surgical Oncology, I.R.C.C.S Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco 65, 70124, Bari, Italy


Abstract

Background: Consensus on the nomenclature and indications for reoperation for post-operative pancreatic fistula (POPF) after pancreatoduodenectomy (PD) is lacking. This study explores the available literature to classify the different types of reoperations and report outcomes.

Methods: A systematic literature search was performed, including articles from 2010 to 2024 reporting reoperations for POPF after PD. The primary outcome was 30- or 90-day-mortality. Secondary outcomes included reoperation date, additional relaparotomy, ICU-admission, hospital stay, rate of pancreatic-exocrine-insufficiency, diabetes and long-term survivors.

Results: Twenty-five studies were reviewed with 766 patients reoperated for POPF after PD, 283 (37 %) undergoing completion pancreatectomy (CP) and 483 (63 %) pancreas-preserving-procedures (PPPs). Among PPPs, drainage (30 %), wirsungostomy (14 %), pancreatic anastomosis repair (6 %), “sinking” of pancreatic stump (6 %) and re-do pancreatic anastomosis (4 %) were identified. The main indications for reoperation were post-pancreatectomy hemorrhage, necrotizing acute pancreatitis, sepsis and peritonitis. PPPs were preferred with severe hemodynamic instability. Mortality rates after CP and PPPs ranged from 20 to 56 % and 0–67 %, respectively. Early reoperation was associated with reduced ICU-recovery after “sinking” ($p = 0.049$).

Conclusion: Reoperation for POPF after PD is rarely needed. When it is, early timing seems critical for better outcomes, and PPPs seems to be the best bail out option in patients with severe hemodynamic instability.



Severe hemodynamic instability was the most common indication

Main indications were Sepsis (22.3%), PPH (17.3%)




PANCREAS-PRESERVING PROCEDURES (PPP)

COMPLETION PANCREATECTOMY (CP)

Simple drainage

Repair/Re-do PJ




Sinking



Wirsungostomy (internal)

Wirsungostomy (external)

Salvage PG



30 % further relaparotomy rate and 2-48 % mortality rate

Largest series is 68 patients, a second relaparotomy was necessary in 13.3 % of cases and the mortality rate was 33.3 %.

Further relaparotomies were necessary in 23.1 %, the mortality rate was 15.3 %, 7.7% develop DM and 77% developed PEI

5 cases report, 80 % of patients survived without diabetes
No dead

Widely mortality rate 0 – 67%
Decrease blood loss and operative time
Need technically demand depend by center experience

More Frequent postoperative DM
Mortality rate 7 – 40%
Early re-operation was significant decrease (63% to 30%)

no patient required relaparotomy or died




Figure 2 Decision making flow-chart for reoperation in patients with POPF after PD Abbreviations: POPF, post operative pancreatic fistula; PD, pancreateo-duodenectomy; PPAP, post pancreatectomy acute pancreatitis; PPH, post pancreatectomy hemorrhage; POD, post operative day; PJ, pancreatico-jejunostomy; PG, pancreatico-gastrostomy
HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

Take home message for POPF

- Definition : Drain amylase > 3 times ULN on/after POD3
- Grading : ISGPS 2016
 - Grade B : persistent drainage > 3 weeks, PCD, endoscopic management, angiographic procedure, signs of infection
 - Grade C : Reoperation, Organ failure, Death
- No proven strategies for decrease incidence of grade B+C POPF
- Management :
 - Conservative
 - Surgery : may be performed in patients with hemodynamic instability or sepsis

Postpancreatectomy hemorrhage(PPH)

- Definition,
“Postoperative hemorrhage after pancreatic resection including intraabdominal hemorrhage and gastrointestinal hemorrhage”
- Incidence 0.8 - 16.1 %
- Mortality-related PPH rate 0% - 30.8 %
- Ramathibodi hospital, incidence 9.3%

Postpancreatectomy hemorrhage

- Defined by 3 parameters;
 - Onset
 - Location
 - Severity



Postpancreatectomy hemorrhage

- Defined by 3 parameters;
 - Onset : Early(within 24 hours) vs Late(more than 24 hours)
 - Location
 - Severity

Postpancreatectomy hemorrhage

Early onset (within 24 hours)


- Technical failure
 - Inadequate hemostatic at time of surgery
 - A slipped ligature
 - Bleeding from anastomosis
- Underling coagulopathy
 - Diffuse hemorrhage from retroperitoneum
 - Jaundice

Late onset (more than 24 hours)

- Mortality rates ranged from 15% to 58%
- Complex pathogenesis
 - surgical trauma (including vascular skeletonization during lymphadenectomy)
 - vascular erosion secondary to anastomotic leakage
 - intra-abdominal abscess
 - pseudoaneurysm formation
 - intraluminal ulcerations

Postpancreatectomy hemorrhage

- Defined by 3 parameters;
 - Onset : Early(within 24 hours) vs Late(more than 24 hours)
 - Location : Right vs Left pancreatic resection, Intraluminal vs Extraluminal
 - Severity



Right side
pancreatic resection


Left side
pancreatic resection

A systematic review of post-pancreatectomy haemorrhage management stratified according to ISGPS grading

Thomas A. Maccabe¹, Harry F. Robertson¹, James Skipworth¹, Jonathan Rees¹, Keith Roberts^{1,2} & Samir Pathak¹


¹Department of Hepatopancreatobiliary Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, and

²Department of Pancreatic Surgery, University Hospitals Birmingham, UK



Early PPH

- Pancreatic remnant in 41.2%(7/17)



Late PPH

- GDA stump in 27.4%
- CHA in 21.4%
- Pancreatic remnant in 9.3%

Postpancreatectomy hemorrhage

- Location

- Intraluminal

- anastomosis suture line at stomach or duodenum
 - pancreatic surface at anastomosis
 - stress ulcer
 - pseudoaneurysm

- Extraluminal

- anastomosis suture line at stomach or duodenum
 - pancreatic surface at anastomosis
 - stress ulcer
 - pseudoaneurysm

Postpancreatectomy hemorrhage

- Defined by 3 parameters;
 - Onset : Early(within 24 hours) vs Late(more than 24 hours)
 - Location : Right vs Left pancreatic resection, Intraluminal vs Extraluminal
 - Severity : Mild vs Severe

Severity of Hemorrhage

Mild

- Small or medium volume blood loss (from drains, nasogastric tube, or on ultrasonography, decrease in hemoglobin concentration <3 g/dl)
- Mild clinical impairment of the patient, no therapeutic consequence, or at most the need for noninvasive treatment with volume resuscitation or blood transfusions (2-3 units packed cells within 24 h of end of operation or 1-3 units if later than 24 h after operation)
- No need for reoperation or interventional angiographic embolization; endoscopic treatment of anastomotic bleeding may occur provided the other conditions apply

Severe

- Large volume blood loss (drop of hemoglobin level by ≥ 3 g/dl)
 - Clinically significant impairment (eg, tachycardia, hypotension, oliguria, hypovolemic shock), need for blood transfusion (>3 units packed cells)
 - Need for invasive treatment (interventional angiographic embolization, or relaparotomy)
-

Table II. Proposed classification of PPH: clinical condition, diagnostic and therapeutic consequences

<i>Grade</i>	<i>Time of onset, location, severity and clinical impact of bleeding</i>		<i>Clinical condition</i>	<i>Diagnostic consequence</i>	<i>Therapeutic consequence</i>
A	Early, intra- or extraluminal, mild		Well	Observation, blood count, ultrasonography and, if necessary, computed tomography	No
B	Early, intra- or extraluminal, severe	Late, intra- or extraluminal, mild*	Often well/ intermediate, very rarely life-threatening	Observation, blood count, ultrasonography, computed tomography, angiography, endoscopy†	Transfusion of fluid/ blood, intermediate care unit (or ICU), therapeutic endoscopy,† embolization, relaparotomy for early PPH
C		Late, intra- or extraluminal, severe	Severely impaired, life-threatening	Angiography, computed tomography, endoscopy†	Localization of bleeding, angiography and embolization, (endoscopy†) or relaparotomy, ICU

Reappraisal of post-pancreatectomy hemorrhage (PPH) classifications: do we need to redefine grades A and B?

Alvaro A. Duarte Garcés^{1,2}, Stefano Andrianello², Giovanni Marchegiani², Roberta Piccolo², Erica Secchettin², Salvatore Paiella², Giuseppe Malleo², Roberto Salvia² & Claudio Bassi²

¹Departamento Cirugía Hepato Biliar y Pancreatica, Hospital Pablo Tobon Uribe, Medellín, Colombia, and ²General and Pancreatic Surgery – The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy

		Cohort without PPH (n = 2264)	A (n = 21)	B (n = 100)	C (n = 44)	P
Sex	M	1137 (50.2%)	8 (38.1%)	55 (55%)	28 (63.6%)	0.3
	F	1127 (49.8%)	13 (61.9%)	45 (45%)	16 (36.4%)	
Age		61 (20–77)	59 (33–62)	60 (24–77)	60 (24–77)	0.4
BMI		23 (17.5–35.2)	25.3 (18–32.2)	23 (19–35.2)	23 (17–31.2)	0.7
Type of surgery	Whipple	1378 (60.8%)	15 (71.4%)	71 (71%)	34 (77.2%)	0.5
	DP	624 (27.5%)	4 (19%)	18 (18%)	6 (13.6%)	
	TP	100 (4.4%)	2 (9.5%)	6 (6%)	0	
	Limited resections	162 (7.1%)	0	4 (4%)	4 (9%)	
POPF		158 (7%)	3 (14.3%)	25 (25%)	18 (63.6%)	<0.01
Abscess		393 (17.4%)	7 (33.3%)	47 (47%)	29 (65.9%)	0.04
BF		51 (2.3%)	1 (4.8%)	7 (7%)	11 (25%)	<0.01
POAP		68 (3%)	0	12 (12%)	13 (29.5%)	0.01
EF		30 (1.3%)	0	7 (7%)	9 (20.5%)	0.04
DGE		105 (4.6%)	2 (10%)	9 (9%)	8 (18.6%)	<0.01
ICU stay		0	1 (4.8%)	18 (18%)	18 (41.9%)	<0.01

LHS (median, range)
Mortality
Readmission
Site of PPH
Management
Ob

Table 1 PPH definition according to the ISGPS⁸

Time of onset	Early	<24 h from surgery
	Late	>24 h from surgery
Location	Intraluminal	Intra-enteric
	Extraluminal	Bleeding in the abdominal cavity or evident by drains
Severity	Mild	- Small amount of blood from NGT, drains or at US
		- Hgb drop <3 g/dL
		- Mild clinical impairment
		- No therapeutic consequence
		- 2–3 PRBC if < 24 h from surgery
		- 1–3 if > 24 h from surgery
	Severe	- large blood loss
		- Hgb drop > 3 g/dL
		- Significant clinical impairment
		- > 3 PRBC
		- invasive treatment
Grade A	Early	- no clinical impairment
	Mild	- observation
		- no therapeutic consequence
Grade B	Early and severe or Late and mild	- Rarely life-threatening
		- CT scan, angiography, endoscopy
		- Endoscopy, embolization
		- Angiography, embolization, or severe PPH

Grade A PPH shared the same outcome of patients without PPH. Grade B PPH included two categories of patients with different treatment modalities

Postpancreatectomy hemorrhage

- Prevention techniques
 - 5 RCT reported in strategies that significantly reduced the rate of PPH after PD
 - small jejunal incision
 - falciform ligament wrap around the gastroduodenal artery stump
 - pancreaticojejunostomy (vs pancreaticogastrostomy)
 - perioperative pasireotide administration
 - algorithm-based postoperative patient management
 - No significant reported to reduced the rate of PPH after distal pancreatectomy

End-to-side duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy

A comparison trial of small *versus* larger jejunal incision.
A single center experience

F. Francesco di Mola^{*/**}, Tommaso Grottola^{*/**}, Paolo Panaccio^{*}, Francesca Tavano^{***}, Antonio De Bonis^{**}, Maria Rosa Valvano^{***}, Pierluigi di Sebastiano^{*/**}

^{*}Unit of General and Oncological Surgery, Casa di Cura Pierangeli, University G. D'Annunzio Pescara, Italy

^{**}Department of Surgery IRCCS, Hospital "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy

^{***}Division of Gastroenterology, IRCCS, Hospital "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy



Ann. Ital. Chir., 2020 91, 5: 469-477
pii: S0003469X20032996





Fig. 1: Large Jejunal Incision (LJI)

TABLE III - Postoperative course and complications of 48 patients who underwent pancreaticoduodenectomy

	Group LJI n=22	Group SJI n=26	P-value
Pancreatic fistula, y/n (%y)	3/19 (13,6)	1/25 (4)	0.341
PPH, y/n (%y)	8/14 (36)	2/24 (8)	*0.018
DGE, y/n (%y)	5/17 (23)	4/22 (15)	0.389
Therapy with Octreotide (days), median (IOR)	7 (5-10)	6 (5-7)	*0.040
Removal of left drainage			
Postoperative hospital stay			
Amylase content in drain			

PPH: Post-pancreatectomy



Small jejunal incision groups was significant reduced the rate of PPH

OPEN **Prevention of postpancreatectomy hemorrhage after laparoscopic pancreaticoduodenectomy by wrapping ligamentum teres hepatis surrounding hepatic portal artery**

Zhicheng Wang^{1,2,3}, Yong Wang^{1,3}, Chao Zhu¹, Hongtao Pan¹, Shilei Chen¹, Xiaosi Hu¹, Shuai Zhou¹, Huichun Liu¹, Qing Pang¹ & Hao Jin^{1,3}




BJS, 2022, 109, 37–45

DOI: 10.1093/bjs/znab363

Advance Access Publication Date: 8 November 2021

Randomized Clinical Trial



445 patients were randomized in 2 groups

Per protocol analysis showed a significant reduction in the intervention group (odds ratio 0.09 to 0.7)

Arterial coverage with omental flap was significant reduced the rate of PPH

Retromesenteric omental flap as arterial coverage in pancreaticoduodenectomy: A novel technique to prevent postpancreatectomy hemorrhage

Lancelot Marique, MD, Tatiana Codjia, MD, Jeanne Dembinski, MD, Safi Dokmak, MD, PhD, Beatrice Aussilhou, MD, François Jehaes, MD, François Cauchy, MD, Mickaël Lesurtel, MD, PhD, Alain Sauvanet, MD*

Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, APHP, University of Paris Cité, Clichy, France

OXFORD

Pancreatoduodenectomy with or without prophylactic falciform ligament wrap around the hepatic artery for prevention of postpancreatectomy hemorrhage: a randomized clinical trial

Thilo Welsch^{1,*}, Benjamin Anna Klimova³, Nicole Treb, Jörg Kleeff², Octavian Popes, Maximilian Brunner¹⁰, Henr

Management


- Depend on grading and center experience



Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Pancreatology

journal homepage: www.elsevier.com/locate/pan




Diagnosis and management of postpancreatectomy hemorrhage: A single-center experience of consecutive 1,096 pancreatoduodenectomies


Kosuke Kobayashi ^a, Yosuke Inoue ^{a,*}, Kojiro Omiya ^a, Shoki Sato ^a, Tomotaka Kato ^a, Atsushi Oba ^a, Yoshihiro Ono ^a, Takafumi Sato ^a, Hiromichi Ito ^a, Kiyoshi Matsueda ^b, Akio Saiura ^c, Yu Takahashi ^a

^a Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

^b Department of Diagnostic Ultrasound, Interventional Radiology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

^c Department of Hepatobiliary and Pancreatic Surgery, Juntendo University School of Medicine, Tokyo, Japan





Laparotomy was indicated in

- Early extraluminal PPH
- Patients whom no imaging modality or physical examination could identify the source of bleeding
- Hemodynamic unstable

Take home message for PPH

- Definition : postoperative hemorrhage after pancreatic resection
- Grading depend on onset, location and severity
- Management
 - Resuscitation
 - Intervention : Endoscopy vs angioembolization
 - Laparotomy : early extraluminal PPH, Hemodynamic unstable

Delayed gastric emptying(DGE)

- Definition

“The inability to tolerate solid food **or** prolonged nasogastric tube requirement.”

Table II. Consensus definition of DGE after pancreatic surgery

<i>DGE grade</i>	<i>NGT required</i>	<i>Unable to tolerate solid oral intake by POD</i>	<i>Vomiting/gastric distension</i>	<i>Use of prokinetics</i>
A	4–7 days or reinsertion > POD 3	7	±	±
B	8–14 days or reinsertion > POD 7	14	+	+
C	>14 days or reinsertion > POD 14	21	+	+

- Incidence 3.2 – 59% (Average clinically relevant DGE (grades B and C) in 46 studies with 10013 cases was 14.3%)

Table III. Parameters for grading of DGE

<i>DGE</i>	<i>Grade A</i>	<i>Grade B</i>	<i>Grade C</i>
Clinical condition	Well	Often well/minor discomfort	Ill/bad/severe discomfort (increased overall risk owing to complications and procedures)
Comorbidities	No	Possibly yes (pancreatic leak or fistula, intraabdominal abscess)	Possibly yes (pancreatic leak or fistula, intraabdominal abscess)
Specific treatment	Possibly yes (prokinetic drugs)	Yes (prokinetic drugs, potential reinsertion of NGT)	Yes (prokinetic drugs, NGT)
Nutritional support (enteral or parenteral)	Possibly yes (slower return to solid food intake)	Yes (partial parenteral nutrition)	Yes (total parenteral or enteral nutrition via NGT, prolonged, i.e., >3 weeks postoperatively)
Diagnostic evaluation	No	Possibly yes (endoscopy, upper GI contrast study, CT)	Yes (endoscopy, upper GI contrast study, CT)
Interventional treatment	No	No	Possibly yes (e.g., abscess drainage, relaparotomy for complication, relaparotomy for DGE)
Prolongation of hospital stay	Possibly yes	Yes	Yes
Delay of potential adjuvant therapy	No	No	Yes

Delayed gastric emptying(DGE)

Surgical technique and DGE


- PPPD vs Standard PD
 - There was no difference in the DGE rates between PPPD and standard PD in a Cochrane review by Diener et al
- Pylorus and DGE
 - Hypothesis : rate of DGE was increase in PPPD group due to pyloric spasm
 - Few meta-analysis(retrospective data) : SSPD was decrease rate of DGE when compare with PPPD
 - SSPD vs Whipple operation still unknown

Delayed gastric emptying(DGE)

- Billroth I vs Billroth II vs Roux-en-Y reconstruction
 - No statistically significant difference in the rate of DGE grade B/C between Roux-en-Y compared to Billroth (overall OR 1.83 [CI 95% 0.76-4.42], $p=0.18$).
- Antecolic vs retrocolic gastrojejunal anastomosis
 - Zhou et al. meta-analysis : recruited 5 RCTS, 534 patients showed that no significant difference in route of GJ anastomosis(odds ratio, 0.66; 95 % confidence interval, 0.32 to 1.33; $P = 0.24$)

Delayed gastric emptying(DGE)

- Braun's enteroenterostomy
 - Clinically relevant DGE (grades B and C) was marginally more frequent in the No-Braun group (23.3% vs. 3.3%, $P = 0.052$).
 - In a multivariable analysis, No-Braun anastomosis was an independent risk factor for developing clinically relevant DGE (odds ratio = 16.489; 95%CI[1.287, 211.195]; $P = 0.031$).





Delayed gastric emptying after pancreatoduodenectomy: One complication, two different entities

Giovanni Marchegiani, MD, PhD^a, Anthony Di Gioia, MD^a, Tommaso Giuliani, MD^a, Michela Lovo, MD^a, Eleonora Vico, MD^b, Marco Cereda, MD^b, Claudio Bassi, MD^{a,*}, Luca Gianotti, MD, PhD^b, Roberto Salvia, MD, PhD^a

^a Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, "Giambattista Rossi" Hospital - Borgo Roma, Verona, Italy

^b Unit of Hepatobiliary Pancreatic Surgery, Department of Surgery, San Gerardo Hospital, School of Medicine and Surgery, Milano-Bicocca University, Monza, Italy

Primary DGE : otherwise

Secondary DGE : occurring contemporarily or immediately afterward (<5 days) with the development of another complication including perigastric collection, POPF, PPH, chyle leak, biliary leak, and gastric outlet obstruction

Intraoperative findings

		Total (N = 1170)	No DGE (N = 982) 83.9%	DGE (n = 188) 16.1%	P value
PD type	Pylorus-preserving	899 (76.8%)	769 (78.3%)	130 (69.1%)	.008
	Whipple	271 (23.2%)	213 (21.7%)	58 (30.9%)	
PD type of reconstruction	PJ	1085 (92.7%)	919 (93.6%)	166 (88.3%)	.014
	PG	85 (7.3%)	63 (6.4%)	22 (11.7%)	
Vascular resection		154 (13.2%)	135 (13.7%)	19 (10.1%)	.196
Total operative time (min, median, IQR)		417 (362–475)	415 (360–470)	427 (380–480)	.005
Gland texture	Firm	536 (45.8%)	479 (48.8%)	57 (30.3%)	< .005
	Soft	634 (54.2%)	503 (51.2%)	131 (69.7%)	
Main pancreatic duct diameter (mm, median, IQR)		4 (3–5)	4 (3–5)	3 (2–4)	< .005
Estimated blood loss (mL, median, IQR)		400 (300–600)	400 (300–600)	483 (300–785)	< .005
FRS (median, IQR) ²¹		4 (2–6)	3 (2–5)	5 (3–7)	< .005
FRS (risk zone)	Negligible/Low risk (0–2)	392 (33.5%)	355 (36.2%)	37 (19.7%)	< .005
	Intermediate risk (3–6)	630 (53.8%)	531 (54.1%)	99 (52.7%)	
	High risk (7–10)	149 (12.7%)	97 (9.9%)	52 (27.7%)	
Need for intraoperative blood transfusions		123 (10.5%)	89 (9.1%)	34 (18.1%)	< .005
Lymphadenectomy (harvested nodes, median, IQR)		39 (29–48)	39 (29–49)	38 (28–47)	.226
Optimal lymphadenectomy (>28 nodes) ³⁷		932 (79.7%)	783 (79.7%)	149 (79.3%)	.842

DGE, delayed gastric emptying; FRS, fistula risk score; PD, pancreatoduodenectomy; PJ, pancreaticojejunostomy; PG, pancreaticogastrostomy.

Table IV

Comparison between primary and secondary DGE

		Total (N = 188)	Primary DGE (N = 53, 28.2%)	Secondary DGE (N = 135, 71.8%)	P value
DGE ISGPS grade ⁵	Grade A	34 (18.1%)	16 (30.2%)	18 (13.3%)	< .005
	Grade B	92 (48.9%)	30 (56.6%)	62 (45.9%)	
	Grade C	62 (33.0%)	7 (13.2%)	55 (40.8%)	
CR DGE		154 (81.9%)	37 (69.8%)	117 (86.7%)	.011
DGE ACB (SD)		0.296 (0.09)	0.279 (0.10)	0.303 (0.09)	.256
Day of onset (median, IQR)		5 (3–7)	4 (2–8)	5 (3–7)	.243
Day of resolution (median, IQR)		13 (9–21)	11 (9–14)	14 (10–25)	.007
Time to resolution (d, median, IQR)		8 (5–14)	6 (4–10)	9 (5–17)	.009
Use of total parenteral nutrition		150 (79.8%)	42 (79.2%)	108 (80%)	1.000
Duration of parenteral nutritional support (d, median, IQR)		10 (6–20)	6 (4–10)	13 (8–24)	< .005
Use of enteral nutrition		143 (76.1%)	30 (56.6%)	113 (83.7%)	< .005
Duration of enteral nutritional support (d, median, IQR)		11 (6–18)	7 (4–10)	12 (7–20)	.016

The primary form resolves earlier, and its occurrence might be reduced by pylorus preservation. For the secondary form, clinicians should focus on preventing and treating other trigger complications

Delayed gastric emptying(DGE)

- Management
 - Work up :
 - CT for evaluate collection
 - Upper GI swallowing or EGD for evaluate mechanical obstruction
 - NG tube for decompression
 - The time of removal of NGT was determined when drainage is less than 500mL/day.
 - Motilin receptors agonists like erythromycin have shown to decrease postoperative DGE
 - If DGE persists, endoscopic insertion of a jejunal feeding tube
 - Correct cause

Post pancreatectomy acute pancreatitis (PPAP)

- ISGPS 2022 Definition

“acute inflammatory condition of the pancreatic remnant occurring in the setting of a partial pancreatic resection and initiated early in the perioperative period within the first 3 PODs.”

- POH (Postoperative Hyperamylasemia)

“As only biochemical evidence, POH had, by definition, no clinically relevant impact. Notably, POH did not result in any deviation in the normal postoperative recovery course.”


Postpancreatectomy Acute Pancreatitis (PPAP)

Definition and Grading From the International Study Group for Pancreatic Surgery (ISGPS)

Giovanni Marchegiani, MD, PhD,* Savio George Barreto, MD,† Elisa Bannone, MD,* Michael Sarr,‡
Charles M. Vollmer,§ Saxon Connor,¶ Massimo Falconi,|| Marc G. Besselink,# Roberto Salvia,*
Christopher L. Wolfgang,** Nicholas J. Zyromski,†† Charles J. Yeo,‡‡ Mustapha Adham,§§
Ajith K. Siriwardena,|||| Kyoichi Takaori,¶¶ Mohammad Abu Hilal,## Martin Loos,*** Pascal Probst,***
Thilo Hackert,*** Oliver Strobel,*** Olivier R. C. Busch,# Keith D. Lillemoe,††† Yi Miao,‡‡‡
Christopher M. Halloran,§§§ Jens Werner,||||| Helmut Friess,¶¶¶ Jakob R. Izbicki,####
Maximillian Bockhorn,**** Yogesh K. Vashist,†††† Kevin Conlon,‡‡‡‡ Ioannis Passas,§§§§ Luca Gianotti,|||||||
Marco Del Chiaro,¶¶¶¶ Richard D. Schulick,##### Marco Montorsi,***** Attila Oláh,†††††
Giuseppe Kito Fusai,‡‡‡‡‡ Alejandro Serrablo,§§§§§ Alessandro Zerbi,||||||| Abe Fingerhut,¶¶¶¶¶
Roland Andersson,##### Robert Padbury,† Christos Dervenis,‡‡‡‡ John P. Neoptolemos,*** Claudio Bassi,*✉
Markus W. Büchler,*** and Shailesh V. Shrikhande|||||||, on behalf of the International Study Group for
Pancreatic Surgery

TABLE 1. The ISGPS classification and grading of PPAP

	Biochemical features	Radiologic features ^{†,53}	Grade	Clinical impact
PPAP Postpancreatectomy acute pancreatitis	Sustained (that persists for at least 48 h) serum amylase* activity > the institutional upper limit of normal	Yes	GRADE B	Mild or moderate complications that require: - Acute medical treatment (eg, antibiotics, steroids, supplementary nutritional support), - Interventional radiology and / or endoscopic-guided drainage and/or angiographic procedures.
		Yes	GRADE C	Severe life-threatening complications that lead to: persistent organ failure (of at least 48 h), possibly leading to intensive care admission; surgical intervention; or death.




Post pancreatectomy acute pancreatitis (PPAP)

Retrospective studies

- PPAP may also lead to other local complications especially peripancreatic collections and PPH developing severe morbidity showed concurrent complications.
- Postpancreatectomy necrotizing pancreatitis is extremely rare

	POAP		P
	No (n = 129)	Yes (n = 163)	
Clavien–Dindo \geq IIB	5 (3.8%)	23 (14.1%)	<0.01
POPF	6 (4.7%)	59 (36.2%)	<0.01
B	4 (4.1%)	46 (35.4%)	<0.01
C	2 (2.4%)	13 (10.3%)	
PPH	8 (6.2%)	21 (12.9%)	0.04
A	1 (12.5%)	3 (14.3%)	<0.01
B	6 (75%)	11 (52.4%)	
C	1 (12.5%)	7 (33.3%)	
DGE	16 (12.4%)	22 (13.5%)	0.8
A	3 (18.8%)	0	0.08
B	7 (43.8%)	12 (54.5%)	
C	6 (37.5%)	10 (45.5%)	
Abscess	17 (13.2%)	75 (46%)	<0.01
Chyle leak	1 (0.8%)	9 (5.5%)	0.03
Biliary fistula	4 (3.1%)	11 (6.7%)	0.2
Sepsis	8 (6.2%)	26 (16%)	0.01
Pneumonia	14 (10.9%)	38 (23.3%)	<0.01
Cardiac morbidity	4 (3.1%)	18 (11%)	0.02
Wound infection	13 (10.1%)	28 (17.2%)	0.08
Relaparotomy	5 (3.9%)	20 (12.3%)	0.01
ICU stay	7 (5.4%)	19 (11.7%)	0.04
Mortality at 90 d	2 (1.6%)	11 (6.7%)	0.03
Readmission	3 (2.3%)	11 (6.7%)	0.06
Serum pancreatic amylase (U/L, median, range)			
POD0	11 (0 – 52)	114 (53 – 934)	< 0.01
POD1	7 (0 – 46)	186 (53 – 973)	< 0.01
Drain amylase (U/L, median, range)			
POD1	164 (20 – 7500)	3042 (101 – 7500)	< 0.01
POD5	22 (13 – 7500)	163 (10 – 7500)	0.1
C-reactive protein (mg/L, median, range)			
POD1	88 (8 – 253)	101 (3 – 316)	0.07
POD2	152 (26 – 359)	220 (32 – 297)	< 0.01
POD3	122 (20 – 443)	219 (40 – 507)	< 0.01

DGE indicates delayed gastric emptying.



Post-pancreatectomy acute pancreatitis after pancreatoduodenectomy: Analysis of a clinically-relevant complication in a single-center retrospective study

Ruben Bellotti ^a, Daniel Pably ^a, Dagmar Morell-Hofert ^b, Benno Cardini ^a, Rupert Oberhuber ^a, Eva Braunwarth ^a, Christian Margreiter ^a, Thomas Resch ^a, Dietmar Öfner ^a, Stefan Schneeberger ^a, Manuel Maglione ^{a,*}

^a Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria

^b Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria

Table 4

Patient outcomes stratified by PPAP and CR-POPF occurrence.

Characteristics	CR-POPF-/PPAP-(n = 205)	CR-POPF-/PPAP+(n = 18)	<i>p</i> ^a	CR-POPF+/PPAP-(n = 27)	CR-POPF+/PPAP+(n = 22)	<i>p</i> ^{**}	<i>p</i> ^{***}
Completion Pancreatectomy	0 (0.0)	0 (0.0)	1.000	7 (25.9)	7 (31.8)	0.650	0.008
Biliary leakage	8 (3.9)	1 (5.6)	0.733	4 (14.8)	3 (13.6)	0.907	0.397
DGE	33 (16.1)	5 (27.8)	0.206	8 (29.6)	9 (40.9)	0.409	0.386
PPH	20 (9.8)	7 (38.9)	<0.001	11 (40.7)	12 (54.5)	0.336	0.324
Wound infection	21 (10.2)	3 (16.7)	0.399	10 (37.0)	6 (27.3)	0.468	0.424
Pleural effusion	48 (23.4)	6 (33.3)	0.346	14 (51.9)	11 (50.0)	0.897	0.289
Re-Laparotomy	25 (12.3)	7 (38.9)	0.002	12 (44.4)	10 (45.5)	0.944	0.676
Clavien-Dindo ≥ 3a	44 (21.5)	10 (55.6)	0.001	27 (100.0)	22 (100.0)	1.000	<0.001
Hospital stay[§]	14 (6–137)	21.5 [12–32]	<0.001	35 (7–97)	32.5 (18–100)	0.874	0.004
ICU costs (Euro)[§]	2332.8 (0–91888.0)	3620.4 (0–42416.0)	0.029	8854.2 (1631.0–140317.0)	9985.6 (1647.0–75499.0)	0.568	0.153
Total costs (Euro)[§]	18870.3 (10267.0–193539.0)	19950.0 (1146.0–69726.0)	0.320	30856.7 (13337.0–252353.0)	30237.2 (17146.0–136674.0)	0.292	0.021
Readmission	40 (19.5)	4 (22.2)	0.782	10 (37.0)	6 (27.3)	0.468	0.714
90 days mortality	5 (2.4)	2 (11.1)	0.043	3 (11.1)	2 (9.1)	0.902	0.832

CR-POPF: clinically relevant postoperative pancreatic fistula; PPAP: post-pancreatectomy acute pancreatitis; DGE: delayed gastric emptying; PPH: post-pancreatectomy hemorrhage; ICU: intensive care units.

^a CR-POPF-/PPAP- vs CR-POPF-/PPAP+, ^{**} CR-POPF+/PPAP- vs CR-POPF+/PPAP+, ^{***} CR-POPF-/PPAP+ vs CR-POPF+/PPAP+; [§] median (range).

Characteristics	No PPAP n (%)	PPAP n (%)	<i>p</i>
CR-POPF	27 (11.6)	22 (55.0)	<0.001
Completion Pancreatectomy	7 (3.0)	7 (17.5)	<0.001
Biliary leakage	12 (5.2)	4 (10.0)	0.231
DGE	41 (17.7)	14 (35.0)	0.012
PPH	31 (13.4)	19 (47.5)	<0.001
Wound infection	31 (13.4)	9 (22.5)	0.132
Pleural effusion	62 (26.7)	17 (42.5)	0.042
Re-Laparotomy	37 (15.9)	17 (42.5)	<0.001
Clavien-Dindo ≥ 3a	66 (28.4)	32 (80.0)	<0.001
Hospital stay^a	14.5 (6–137)	24.5 (12–100)	<0.001
Readmission	50 (21.6)	10 (25.0)	0.627
90 days mortality	8 (3.4)	4 (10.0)	0.062

Post hepatectomy hemorrhage

- ISGLS 2011 Definition

“Hb drop >3 g/dl post-operatively compared with post-operative baseline level and/or any post-operative transfusion of PRBCs for a falling Hb and/or the need for invasive re-intervention (e.g. embolization or re-laparotomy) to stop bleeding.”

- Incidence 4.2-10%

Post hepatectomy hemorrhage

Table 2 Consensus proposal of the ISGLS for the definition and severity grading of post-hepatectomy haemorrhage (PHH)

Definition Post-hepatectomy haemorrhage (PHH) is defined as a drop of haemoglobin level >3 g/dl after the end of surgery compared to postoperative baseline level and/or any postoperative transfusion of PRBCs for a falling hemoglobin and/or the need for invasive re-intervention (e.g. embolization or re-laparotomy) to stop bleeding.

To diagnose PHH (and to exclude other sources of haemorrhage) evidence of intraabdominal bleeding should be obtained such as frank blood loss via the abdominal drains if present (e.g. haemoglobin level in drain fluid >3 g/dl) or detection of an intra-abdominal haematoma or active haemorrhage by abdominal imaging (ultrasound, CT, angiography). Patients who are transfused immediately postoperatively for intra-operative blood loss by a maximum of two units of PRBCs (i.e. who do not have evidence of active haemorrhage) are *not* diagnosed with PHH.

Grading	A	PHH requiring transfusion of up to 2 units of PRBCs
	B	PHH requiring transfusion of >2 units of PRBCs but manageable without invasive intervention
	C	PHH requiring radiological interventional treatment (e.g. embolization) or re-laparotomy

Post hepatectomy hemorrhage

Table 3 Common clinical characteristics of patients with different severity grades of post-hepatectomy hemorrhage (PHH)

	Grade A	Grade B^a	Grade C
Clinical condition ^b	Not impaired	Impaired	Life-threatening
Clinical symptoms	No	May have hypotension and tachycardia	May have haemodynamic instability (severe hypotension and tachycardia) Potential hypovolemic shock with organ dysfunction/failure
Adequate response to transfusion of PRBCs ^c	Yes	Yes/no	No
Need for diagnostic assessment	No	Yes	Yes
Radiological evaluation	Possible free intra-abdominal fluid/haematoma	Free intra-abdominal fluid/hematoma May have active bleeding on angiography	Free intra-abdominal fluid/haematoma Active bleeding on angiography
Hospital stay	Commonly not prolonged	Commonly prolonged	Prolonged
Specific treatment	Discontinuation of anticoagulants Intravenous fluid therapy Transfusion of ≤ 2 units of PRBCs	Discontinuation of anticoagulants Intravenous fluid therapy Transfusion of >2 units of PRBCs	Discontinuation of anticoagulants Intravenous fluid therapy Transfusion of PRBCs Vasopressor therapy Embolization and/ or re-laparotomy

Post hepatectomy hemorrhage

- Causes
 - Bleeding from the surfaces of the residual liver
 - Incomplete intraoperative hemostasis
 - Vascular sutures loosened or fallen off

Post hepatectomy hemorrhage

DOI:10.1111/hpb.12255

HPB

ORIGINAL ARTICLE

Post-hepatectomy haemorrhage: a single-centre experience

Aijun Li*, Bin Wu*, Weiping Zhou, Weifeng Yu, Li Li, Hang Yuan & Mengchao Wu

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

- Retrospectively, 77 patients (0.2% of 32 856 hepatectomy patients) for re-exploration from 2001 to 2010
- The most common anatomic site of intra-abdominal haemorrhage
 - cut surface of the liver ($n = 51$, 66.2%)
 - perihepatic ligaments ($n = 19$, 24.7%)
 - splenic fossa ($n = 7$, 9.1%)
 - the diaphragm ($n = 6$, 7.8%)
 - retroperitoneum ($n = 6$, 7.8%)
 - right adrenal gland ($n = 3$, 3.9%)
 - gallbladder bed ($n = 2$, 2.6%).




Figure 1 Time between the initial hepatectomy and return to the operating room

HPB surgery complications: Ativitch Asavachaisuvikom,MD.(F)

Slide 74/78

Post hepatectomy hemorrhage

DOI:10.1111/hpb.12255

HPB

ORIGINAL ARTICLE

Post-hepatectomy haemorrhage: a single-centre experience

Aijun Li*, Bin Wu*, Weiping Zhou, Weifeng Yu, Li Li, Hang Yuan & Mengchao Wu

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

- Timing for return to OR based on surgeon adjustment
- The most common clinical signs of haemorrhage in patients who were returned to the OR after hepatectomy were *blood in the drain postoperative shock and a decrease in serum haemoglobin.*

Reoperation for post-hepatectomy hemorrhage: increased risk of mortality

Chetana Lim • Safi Dokmak • Olivier Farges •
Béatrice Aussilhou • Alain Sauvanet • Jacques Belghiti

- From January 2000 to December 2009, 2,086 elective liver resections were performed in the Department of HBP Surgery and Liver Transplantation at Beaujon Hospital
- Reoperation for bleeding was required in 12 (0.6 %)
- Criteria for re-laparotomy included evidence of blood loss via abdominal drain and/or imaging associated with
 - (1) Hb drop ≥ 3 g/dL from baseline or
 - (2) Hemodynamic instability with continuing requirement of packed red blood.
- The causes of bleeding were the hepatic vein branch (n=4), liver cut surface (n=3), and a hepatic artery branch (n=2). In three cases, no bleeding spot was identified.
- Postoperative death occurred in 3 patients (25 %) between 15 and 18 days after re-laparotomy

Post hepatectomy hemorrhage

Role for embolization?

Insufficient data

May have role in delayed
onset (more than 24 hours)
level of evidence : opinion

The background features a large, light blue circular logo. The outer ring of the logo contains the text "DEPARTMENT OF SURGERY" at the top and "RAMATHIBODI HOSPITAL" at the bottom. In the center of the logo is a caduceus, which consists of a staff with two snakes entwined and wings at the top. The text "Thank you" is written in a large, black, sans-serif font across the center of the slide, partially overlapping the logo.

Thank you